Jefferies has published its research report on Quest Diagnostics DGX following the Jefferies Healthcare Summit yesterday.
According to Jefferies, "Management is working hard to prepare for LT growth by building out its salesforce, expanding its specialty test menu, and improving operating efficiencies. We are watching this story closely as investment timing is key."
Quest's management reemphasized their decision to recontract with managed care through 2012 and noted that it gives their company "unique opportunities to work with their customers to control expensive out-of-network leakage."
Jefferies maintains a Hold rating on DGX. DGX closed Tuesday at $50.12.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in